AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
AstraZeneca AZN announced that it is discontinuing a phase III study called eVOLVE-Lung02, evaluating its experimental bispecific antibody, volrustomig,…
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig
The eVOLVE-Lung02 trial was testing whether volrustomig plus chemotherapy could improve outcomes over the established combination of pembrolizumab…
AstraZeneca Pays $600M for Oral Pill That Beat Chemo in Rare Lung Cancer
For years, patients with a specific genomic subtype of lung cancer faced a stark choice: intravenous chemotherapy, or…
AstraZeneca Secures Global Rights to Lung Cancer Therapy in $600m Deal (AZN)
Medical research ©National Institutes of Health AstraZeneca (LSE:AZN) has agreed to pay Chinese biotechnology company Dizal Pharmaceutical $600…
Abbisko, AstraZeneca to test lumipodlin with Tagrisso
SHANGHAI, July 1, 2026 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter, HKEX code: 02256.HK) today announced…
AstraZeneca (LSE:AZN) Wins Two EU Cancer Approvals And Starts Abbisko Lung Trial
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…